# Nilutamide

Source: https://onco.cc/drugs/nilutamide/  
OnCo record `nilutamide` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nilutamide (Nilandron) is an older antiandrogen tablet started on the day of surgical castration for metastatic prostate cancer; it is rarely used now because of lung and eye side effects.

## Summary

Nilutamide was approved in 1996 for metastatic (stage D2) prostate cancer in combination with surgical castration, with treatment beginning on the day of or the day after orchiectomy, on a randomised trial in which the combination modestly delayed progression compared with castration alone. It has been superseded by bicalutamide and the second-generation antiandrogens. Interstitial pneumonitis (about 2% of patients, more in Japanese men) carries a boxed warning; delayed dark adaptation, alcohol intolerance and hepatitis are also characteristic.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-10
- Also known as: Anandron
- Tags: nci-list; generic
- Brand: Nilandron
- Modality: Non-steroidal antiandrogen (first generation)
- Mechanism: Competitive androgen receptor antagonist without oestrogenic, progestational or glucocorticoid activity.
- Approvals: US 1996: Metastatic (stage D2) prostate cancer in combination with surgical castration

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Nilutamide
- US label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=nilutamide
- NCI drug page: https://www.cancer.gov/about-cancer/treatment/drugs/nilutamide

## Connected records

- drugs: [Bicalutamide](https://onco.cc/drugs/bicalutamide/), [Flutamide](https://onco.cc/drugs/flutamide/)
- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Androgen deprivation & AR pathway inhibitors](https://onco.cc/technologies/androgen-deprivation/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/)
- trials: [Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer](https://onco.cc/trials/nct00003653/), [Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer](https://onco.cc/trials/nct00002633/), [Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer](https://onco.cc/trials/nct03678025/)

---
JSON: https://onco.cc/api/v1/entities/nilutamide.json